Loading clinical trials...
Loading clinical trials...
A Phase 1 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of DCR-PHXC in Patients With Primary Hyperoxaluria Type 3
Conditions
Interventions
DCR-PHXC
Sterile Normal Saline (0.9% NaCl)
Locations
6
United States
Clinical Trial Site
Boston, Massachusetts, United States
Clinical Trial Site
Rochester, Minnesota, United States
Clinical Trial Site
New York, New York, United States
Clinical Trial Site
Bonn, Germany
Clinical Trial Site
Amsterdam, Netherlands
Clinical Trial Site
London, United Kingdom
Start Date
September 14, 2020
Primary Completion Date
September 7, 2021
Completion Date
September 7, 2021
Last Updated
September 19, 2024
Lead Sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions